Pfizer
Merck KGaA and Pfizer team up with Debiopharm in lung cancer treatment
October 21, 2016Medical Communications Debiopharm, Merck KGaA, NSCLC, Pfizer, lung cancer
Debiopharm International, the Swiss-based global biopharmaceutical group of five companies, announced that it would be entering into an agreement with …
Pfizer sets release date for rival to J&J’s blockbuster drug
October 18, 2016Manufacturing and Production J&J, JJ, Johnson & Johnson, Pfizer, Remicade, inflectra
Pfizer have announced that they will begin shipping their rival to Johnson & Johnson’s Remicade by the end of November. …
Pfizer loses UK patent infringement case over $5.1bn drug
October 13, 2016Medical Communications, Sales and Marketing Actavis, Lyrica, Pfizer, patent infringement, pregabalin
Pfizer has been dealt a significant blow as the UK Court of Appeal has rejected the company’s patent infringement claims …
Tesaro’s ovarian cancer drug success threatens market rivals
October 12, 2016Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib
Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …
Transgene announce key partnership with Merck KGaA and Pfizer
October 12, 2016Research and Development Cancer, France, Merck Group, Pfizer, Transgene, avelumab, head, neck
Transgene, a company that designs and developed targeted immunotherapies to treat cancer and infectious diseases, has announced a collaboration agreement …
Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial
October 11, 2016Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma
Phase II results presented by genomics-based discovery company Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …
Novartis’ new drug muscles in on Pfizer’s territory
October 10, 2016Sales and Marketing Eli Lilly, Novartis, Pfizer, ibrance, ribociclib
A drug developed by Novartis, ribociclib, when combined with an older drug, letrozole, has been shown to reduce risk of progression …
ICU Medical to acquire Pfizer’s global infusion therapy business in $1 billion deal
October 6, 2016Medical Communications Hospira, ICU medical, Pfizer, acquisition, infusion
The $1 billion deal that will take place as ICU Medical Inc. take over Pfizer’s Hospira Infusion Systems will be …
Pfizer decides not to break up business
September 26, 2016Sales and Marketing Ian Read, Pfizer, United States, america
In the intervening four years, Pfizer has conducted “extensive evaluation” into the possibility, with the company reorganising into two distinct …
Top Ten articles in the Pharma Industry this week
September 16, 2016Medical Communications Bayer, GSK, Gilead, GlaxoSmithKline, J&J, JJ, Pfizer, Roche, Sanofi, Takeda, aspen, google, monsanto
As we come to the end of another week, we’re looking back at an exciting week in the industry; there …
Pfizer launches legal action to block Xeljanz copies in India
September 9, 2016Medical Communications, Sales and Marketing Pfizer, Sun Pharma, Xeljanz, Zydus Cadila, rheumatoid arthritis
Pfizer has pre-emptively sued a number of India-based drug companies including Sun Pharma and Zydus Cadila to block any attempts …
Pfizer nabs EU approval for Xalkori for certain lung cancers
August 31, 2016Sales and Marketing Pfizer, Xalkori, lung cancer, non-small cell lung cancer
The European Commission has approved Pfizer’s Xalkori (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer …
Pfizer to acquire AstraZeneca’s anti-infective business for $550 million upfront
August 24, 2016Research and Development, Sales and Marketing AstraZeneca, Pfizer, Zavicefta, anti-infective
Pfizer has announced that it is to acquire AstraZeneca’s small molecule anti-infective business in a deal potentially worth up to …
MHRA suspends GMP certificate for Pfizer site in India
August 22, 2016Manufacturing and Production, Sales and Marketing GMP, India, MHRA, Pfizer, ban, facility, import, suspend
The UK’s Medicines and Healthcare Products Agency (MHRA) has recommended that an Indian facility belonging to Pfizer’s Hospira unit be …
Pfizer acquires Medivation for $14 billion
August 22, 2016Sales and Marketing Medivation, Pfizer, acquisition, oncology
Pfizer has sealed the deal to acquire US cancer drug company Medivation for close to $14 billion in a move …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
